Search Results
Dec 11, 2025, 18:09 ET FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021;10(11):2235.Hehir MK, Silvestri NJ. Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology. Neurol Clin. 2018;36:253-260.Bubuioc AM, Kudebayeva A, Turuspekova
More news about: Amgen
Dec 11, 2025, 08:30 ET WERFEN APPLAUDS SIGNIFICANT PUBLICATION URGING ACTION ON THE RISKS OF UNDETECTED HEMOLYSIS
collection facility: opportunities for quality improvement. Clin Chem Lab Med. 2009;47(5):616–618. doi:10.1515/CCLM.2009.132Lippi G, Fontana R, Avanzini P, Sandei F, Ippolito L. Influence of spurious hemolysis on blood gas analysis. Clin Chem Lab Med. 2013;51(8):1651–1654. doi:10.1515/cclm-2012-0802O'Hara
More news about: Werfen
Dec 10, 2025, 14:16 ET Menarini Group apresenta os dados da fase 2 da combinação de elacestranto (ORSERDU®) em pacientes com câncer de mama metastático (mBC) ER+, HER2- no San Antonio Breast Cancer Symposium 2025 (SABCS)
sólidos e hematológicos.[1]Lloyd et al. Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer. Clin Cancer Res (2025).
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 10, 2025, 14:02 ET Menarini Group presenta datos de combinación de fase 2 de Elacestrant (ORSERDU®) en pacientes con cáncer de mama metastásico (CMM) ER+, con HER2 en el Simposio de Cáncer de Mama 2025 en San Antonio
sólidos y hematológicos.[1] Lloyd et al. Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer. Clin Cancer Res (2025).
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 10, 2025, 10:11 ET Menarini Group、2025年サンアントニオ乳がんシンポジウムにてエラセストラント（ORSERDU®）併用療法の第2相データをER+、HER2-転移性乳がん（mBC）患者を対象に発表
乳がんおよび血液がんを適応症とするエラセストラントおよびタグラキソフスプの複数の適応拡大試験も実施しており、固形がんおよび血液がんの多くを対象とする様々な開発段階にある追加の薬剤候補の広範な臨床パイプラインを有しています。[1] Lloyd他：ESR1変異転移性乳がんにおけるエラセストラント治療成績に関連する臨床およびゲノム因子。Clin Cancer Res（2025年）。
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 23:19 ET Il Gruppo Menarini presenta i dati di fase 2 sulla combinazione di elacestrant (ORSERDU®) in pazienti affetti da carcinoma mammario metastatico (mBC) ER+, HER2- al Simposio sul cancro al seno di San Antonio del 2025
solidi ed ematologici.[1] Lloyd et al. Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer. Clin Cancer Res (2025).
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 14:24 ET Menarini Group 於 2025 年聖安東尼奧乳癌研討會公佈 Elacestrant (ORSERDU®) 針對 ER+、HER2- 轉移性乳癌 (mBC) 患者的第 2 期聯合治療數據
作多項標籤擴展研究，並為實體癌症和血液系統癌症病人的其他候選藥物，擁有處於不同研發階段的廣泛臨床管線。[1] Lloyd et al. Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer. Clin Cancer Res (2025).
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 12:00 ET TrilliumBiO and Oncobit Partner to Bring Novel Uveal Melanoma Monitoring Solution to the U.S.
Kadefors M, et al. Immuno-Oncology and Technology. 2025;28(C):101079. doi:10.1016/j.iotech.2025.101079.2 Machiraju D, et al. J Exp Clin Cancer Res. 2025;44:213. doi:10.1186/s13046-025-03451-2.3 Ramelyte E, Koett, J, et al. Clinical Cancer Research. Accepted.TrilliumBiO
More news about: TrilliumBiO
Dec 09, 2025, 11:38 ET El Grupo Menarini presenta datos de la combinación de fase 2 de Elacestrant (ORSERDU®) en cáncer de mama
sólidos y hematológicos.[1] Lloyd et al. Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer. Clin Cancer Res (2025).
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 09:49 ET 메나리니 그룹, 2025 샌안토니오 유방암 심포지엄에서 엘라세스트란트(ORSERDU)®의 ER+, HER2- 전이성 유방암(mBC) 환자 대상 2상 병용 요법 데이터 발표
변이 전이성 유방암에서 엘라세스트란트 치료 성과와 관련된 임상•유전체 요인(Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer). Clin Cancer Res(2025).
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 09:00 ET TrilliumBiO and Oncobit Partner to Bring Novel Uveal Melanoma Monitoring Solution to the U.S.
Kadefors M, et al. Immuno-Oncology and Technology. 2025;28(C):101079. doi:10.1016/j.iotech.2025.101079.2 Machiraju D, et al. J Exp Clin Cancer Res. 2025;44:213. doi:10.1186/s13046-025-03451-2.3 Ramelyte E, Koett, J, et al. Clinical Cancer Research. Accepted.TrilliumBiO
More news about: TrilliumBiO
Dec 08, 2025, 15:17 ET Le groupe Menarini présente les données de la phase 2 sur l'association d'Elacestrant (ORSERDU®) chez des patientes atteintes d'un cancer du sein métastatique (mBC) ER+, HER2- lors du 2025 San Antonio Breast Cancer Symposium
et hématologiques.[1] Lloyd et al. Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer. Clin Cancer Res (2025).
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 14:47 ET Menarini Group präsentiert Daten zur Phase-2-Kombination von Elacestrant (ORSERDU®) bei Patientinnen mit ER+, HER2- metastasiertem Brustkrebs (mBC) auf dem San Antonio Breast Cancer Symposium 2025
Krebsarten.[1] Lloyd et al. Klinische und genomische Faktoren im Zusammenhang mit Elacestrant-Ergebnissen bei ESR1-mutiertem metastasiertem Brustkrebs. Clin Cancer Res (2025).
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 13:41 ET Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
hematologic cancers.[1] Lloyd et al. Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer. Clin Cancer Res (2025).
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 13:30 ET Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
hematologic cancers.[1] Lloyd et al. Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer. Clin Cancer Res (2025).
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 12:00 ET Sumitomo Pharma America Presents New Investigational Data on Enzomenib and Nuvisertib at the 2025 American Society of Hematology Annual Meeting and Exposition
doi:10.1021/acs.jmedchem.8b00071Hernández-Boluda JC, Czerw T. Transplantation algorithm for myelofibrosis in 2022 and beyond. Best Pract Res Clin Haematol. 2022;35(2):101369. doi:10.1016/j.beha.2022.101369Cierpicki T, Grembecka J. Challenges and opportunities in targeting the menin-MLL
More news about: Sumitomo Pharma America
Dec 08, 2025, 08:57 ET Intervention de Cui Li, directrice du développement de ZTE, à la conférence « AI Innovation Asia 2025 » (« Innovation en Asie dans le domaine de l'IA 2025 »), organisée par Economist Impact
par effet boule de neige des remparts solides. Nous devons aussi rester agiles pour repérer les évolutions et être en mesure de changer de cap en un clin d'œil, en transformant l'organisation machinale en structure organique et adaptative.Ensuite, nous devons savoir comment l'IA peut réellement
More news about: ZTE Corporation
Dec 05, 2025, 16:20 ET Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
Mariappan P, Geiges G, Pöhlmann J, Pollock RF. The management of non–muscle-invasive bladder cancer: a comparison of European and UK guidelines. J Clin Urol. 2018;11(2):144-148.5 Babjuk M, Burger M, Capoun O, et al. European Association of Urology Guidelines on Non-muscle-invasive
More news about: Johnson & Johnson
Dec 04, 2025, 11:00 ET Muscles, the New Flex: Abbott Launches Two New Ensure® Max Protein Shakes to Tap into Growing Muscle Health Movement
iiiDeutz NE, et al. Clin Nutr. 2014;33(6):929–36.iv
More news about: Abbott
Dec 03, 2025, 16:56 ET Tendências para 2026: esses são os procedimentos estéticos que estarão em alta para o ano que vem
Poster Presentation, IMCAS 2025.10. Weiss RA, et al. Dermatol Surg. 2016 Jun;42(6):699-709 11. Di Gregorio, C et al. Clin Cosmet Investig Dermatol. 2022 Apr 14;15:681-690. 12. Talarico S, et al. Dermatol Surg. 2015 Dec;41(12):1361-9. 13.
More news about: Galderma
Nov 28, 2025, 04:06 ET China's First Domestic IL-23p19 Monoclonal Antibody: Innovent's PECONDLE® (Picankibart Injection) Received NMPA Approval
ng biologics in psoriasis - practical guidance and evidence to support. Expert Rev Clin Pharmacol. 2020;13(5):493-503. About Psoriasis Psoriasis is a chronic,
More news about: Innovent Biologics
Nov 26, 2025, 01:00 ET Renalys Pharma Announces Positive Topline Results from Phase III Study of Sparsentan in Japanese Patients with IgA Nephropathy
Proteinuria reduction as a surrogate endpoint for clinical study of IgA nephropathy in Japanese patients: data from the J-CKD-DB-Ex.Naoki Kashihara. Clin Exp Nephrol. 2025 Nov 18. doi: 10.1007/s10157-025-02788-4.
More news about: Renalys Pharma, Inc.
Nov 21, 2025, 09:47 ET Cuidados combinados: como o skincare diário e os procedimentos estéticos se complementam para melhorar a qualidade da pele
1-3 February 2024, Paris, France11. Weiss RA et al. Dermatol Surg. 2016 Jun;42(6):699-709 12. Di Gregorio C et al. Clin Cosmet Investig Dermatol. 2022 Apr 14;15:681-690. 13. Talarico S et al. Dermatol Surg. 2015 Dec;41(12):1361-9. 14. Belmontesi
More news about: Galderma
Nov 20, 2025, 12:00 ET MyOme Launches First Integrated Polygenic Risk Score for Prostate Cancer to Advance Early Detection and Personalized Prevention
Andrews KS, Brooks D, et al. Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines.CA Cancer J Clin. 2019;69(3):184–210. U.S. Preventive Services Task Force. Screening for Prostate Cancer: Recommendation Statement.JAMA.
More news about: MyOme, Inc
Nov 20, 2025, 07:17 ET Zendure lance le nouveau système de stockage d'énergie d'entrée de gamme à intelligence artificielle SolarFlow 800 Plus
tension à 14 V augmente la production en faible éclairage de 10 à 20 %. Principales caractéristiques en un clin d'œil : Capacité de base de 1 920 Wh, extensible jusqu'à 11,52 kWh avec cinq batteries
More news about: Zendure DE GmbH